CRO

Prophix Achieves $100M in Annual Recurring Revenue Ahead of Plan; Recaps Significant 2022 Business Momentum

Retrieved on: 
Tuesday, November 15, 2022
People, Veteran, Growth, CRO, Goal, Certification, Organization, ARR, Construction, MISSISSAUGA, History, Industry, HG Capital, Time, Forecasting, Business performance management, CPM, CEO, Risk, CSR, Microsoft, AI, CMO, Solution, Management, Renewable energy, Risk management, Hg

MISSISSAUGA, ON , Nov. 15, 2022 /PRNewswire/ -- Prophix, a global leader in Corporate Performance Management (CPM) software, today announced the company has surpassed $100 million in Annual Recurring Revenue (ARR). "In 2018, we set an aggressive goal to become the mid-market leader in our segment and, more importantly, reach the $100M mark by 2023. At the time, growing 40x revenue seemed an audacious target, which makes it all the more gratifying to achieve, particularly well ahead of schedule," said Alok Ajmera, President & CEO, Prophix. "Throughout our history, Prophix has been a balanced, high-growth company, making the right investments to support our customers while achieving our aggressive growth goals. In today's volatile economic environment, this strategy continues to pay off."

Key Points: 
  • At the time, growing 40x revenue seemed an audacious target, which makes it all the more gratifying to achieve, particularly well ahead of schedule," said Alok Ajmera, President & CEO, Prophix.
  • In January of 2021, Hg, a leading global software investor, made a significant investment in Prophix.
  • Prophix saw its third quarter 2022 ARR increase by 24% from the same period year-over-year and its cloud customer base grow by over 41%.
  • Prophix also achieved HiTrust Certification, which gives Prophix customers assurance that their mission critical, business sensitive information is secured and protected.

Navix Announces Partnership with Running Ox Logistics to Provide Automated Document Retrieval and Freight Audit Services

Retrieved on: 
Tuesday, November 15, 2022
Friends, ROSA, Industry, API, CRO, Technology, Classification, Documentation, Multimedia, Partnership, Running, Mobile phone, Online shopping

SANTA ROSA BEACH, Fla., Nov. 15, 2022 /PRNewswire/ -- Running Ox Logistics has partnered with Navix to manage and streamline its document retrieval and freight audit process; thereby allowing Running Ox to focus on more strategic efforts, like growing its business all while shortening their cash conversion cycle. With Navix's scalable document retrieval and auditing software-as-a-service platform, Navix eliminates costly billing errors and automates audit processes by handles the process of document ingestion including categorization, order matching, rate audit, customer invoicing, and carrier payment approval. Navix also provides Running Ox Logistics with insights to better understand the invoice-to-audit ratio and the reasons behind those audits, including pricing discrepancies and assessorial charges, at the line-item level.

Key Points: 
  • With Navix's scalable document retrieval and auditing software-as-a-service platform, Navix eliminates costly billing errors and automates audit processes by handles the process of document ingestion including categorization, order matching, rate audit, customer invoicing, and carrier payment approval.
  • Navix also provides Running Ox Logistics with insights to better understand the invoice-to-audit ratio and the reasons behind those audits, including pricing discrepancies and assessorial charges, at the line-item level.
  • Document retrieval, freight audit and payments have been an industry headache for a long time.
  • Running Ox Logistics is a nationwide, multimodal logistics company with a vast carrier network, speed-to-market efficiencies, and unmatched commitment to service.

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
ATM, Security (finance), EUA, University of Pittsburgh Medical Center, Consolidated, Cancer, GNA, Therapy, NCI, Annual report, EST, Blood, Degenerative disease, Infection, IDE, SAN, CRO, COVID, U.S. Securities and Exchange Commission, Board, Government, University, FDA, Contract, Patient, Clinical trial, High-dependency unit, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Securities Act of 1933, EFS, Safety, Emergency Use Authorization, NIH, Head, Director, Drug Quality and Security Act, Food and Drug Administration, ESI, Metastasis, Interest, Neck, Risk, Company, Nasdaq, Insurance, Research, Securities Exchange Act of 1934, UPMC, COVID-19, Internet, Exosome, Review, Food, Disease, Medical device, Vaccine, Pharmaceutical industry, Generic drug, Health insurance, EU

SAN DIEGO, Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.

Key Points: 
  • SAN DIEGO, Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.
  • Financial Results for the Second Quarter Ended September 30, 2022
    As of September 30, 2022, Aethlon Medical had a cash balance of approximately $19.6 million.
  • The Company will hold a conference call today, Monday, Nov.14, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments.
  • Aethlon Medical is a medical therapeutic company developing the Hemopurifier, a therapeutic blood filtration system indicated for cancer and infectious diseases.

Greenberg Traurig's Kemal Hawa to Moderate Two Panels at DICE West 2022

Retrieved on: 
Monday, November 14, 2022
LLP, Lawyer, Conference, CRO, Technology, NLJ, Quantum, Bisnow Media, Industry, AM, Aviation, COO, Center, Center for Resource Solutions, Investment, CEO, DICE, VP, Food, Corporation, Telecommunication, Video game, Financial services, Innovation, Oracle, Microsoft

WASHINGTON, Nov. 14, 2022 /PRNewswire-PRWeb/ -- Kemal Hawa, a global law firm Greenberg Traurig, LLP Corporate shareholder, will moderate two panel discussions at Bisnow's Data Center Investment Conference & Expo (DICE) West event Nov. 30 at the San Jose Marriott.

Key Points: 
  • Kemal Hawa, a global law firm Greenberg Traurig, LLP Corporate shareholder, will moderate two panel discussions at Bisnow's Data Center Investment Conference & Expo (DICE) West event Nov. 30 at the San Jose Marriott.
  • WASHINGTON, Nov. 14, 2022 /PRNewswire-PRWeb/ -- Kemal Hawa , a global law firm Greenberg Traurig, LLP Corporate shareholder, will moderate two panel discussions at Bisnow's Data Center Investment Conference & Expo (DICE) West event Nov. 30 at the San Jose Marriott.
  • Hawa focuses his practice on corporate and securities law with an emphasis on the telecommunications, media, tower, and technology industries domestically and internationally.
  • About Greenberg Traurig: Greenberg Traurig, LLP has more than 2500 attorneys in 43 locations in the United States, Europe, Latin America, Asia, and the Middle East.

MCRA Expands into Anesthesia and Critical Care Therapy Specializations, Hires FDA Assistant Director

Retrieved on: 
Monday, November 14, 2022
Growth, Neurology, General surgery, FDA Center for Devices and Radiological Health, CRO, Elective surgery, PMA, Quality assurance, Leadership, Critical care, Urology, Senior, FDA, Industry, Assistant, View, Center, Contract research organization, Spine, MCRA, DC, IVD, Multimedia, Device, VB, Google Images, Regulatory affairs, Artificial intelligence, Clinical trial, LLC, Review, US Foods, Food, Robotics, Medical device, Risk management, Anesthesia, Computer security

With the growth in the number of medical devices for anesthesia and critical care, MCRA has hired Mr. Courtney as the Vice President of Anesthesia Regulatory Affairs.

Key Points: 
  • With the growth in the number of medical devices for anesthesia and critical care, MCRA has hired Mr. Courtney as the Vice President of Anesthesia Regulatory Affairs.
  • This team will provide expert consultation to clients on medical device submissions in the anesthesia and critical care space.
  • David Lown, MCRA's President said "With the growth in anesthesia-based medical devices, MCRA is proud to expand its therapy specializations to include anesthesia and critical care.
  • MCRA is proud to continue supporting innovation in the medical device industry by helping clients navigate regulatory submissions in the anesthesia and critical care space, both at the FDA and globally.

CATIC Hires New VP & Illinois State Counsel, Katherine F.L. Vyas

Retrieved on: 
Monday, November 14, 2022
CRO, CATIC, SVP, Reading, Stetson University College of Law, University, View, Company, Center, Private practice, General practice, Multimedia, American Land Title Association, VP, American, ALTA, Solution, Insurance, Property management, Facebook

Vyas has joined its Illinois Team in the role of VP & Illinois State Counsel.

Key Points: 
  • Vyas has joined its Illinois Team in the role of VP & Illinois State Counsel.
  • Before joining CATIC, Katherine was the Northwest Area Underwriting Counsel at a national underwriter, where she worked on underwriting complex municipal transactions, multi-site projects, both commercial and residential deals, and led the condominium deconversion team.
  • Prior to becoming an underwriter, she was in private practice, focusing on residential and commercial real estate, litigation, and general practice.
  • While at Stetson, Katherine was the Research Editor of the Stetson Law Review and a Fellow of the Center for Excellence in Advocacy.

Incredibuild Launches New Automotive Solution, Revving Up Industry Software Development at Unrivaled Speeds

Retrieved on: 
Monday, November 14, 2022
Cloud, AOSP, Automotive Grade Linux, SDV, CRO, Software, AGL, Electric vehicle, Developer, ADAS, Organization, Unreal Engine, Safety, QNX, AWS, Efficiency, Carbon, EVS, Industry, Acceleration, Linux kernel, DevOps, TEL, Central processing unit, Linux, Automotive industry, AVS, Google Cloud Platform, Yocto-, Microsoft, Azure, Build automation, Solution, Satellite navigation device, Video game console, QT, Microsoft Windows

TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Incredibuild, maker of the leading development acceleration platform for Developers and DevOps teams, announced today the launch of Incredibuild for Automotive. Incredibuild for Automotive provides significant acceleration and support for the leading software development tools used in the ever-growing Software-Defined Vehicle (SDV) industry – including QNX, AOSP, Yocto, Automotive Grade Linux, Qt, Jenkins, Gitlab, Github Actions and more.

Key Points: 
  • Incredibuild for Automotive provides significant acceleration and support for the leading software development tools used in the ever-growing Software-Defined Vehicle (SDV) industry including QNX, AOSP, Yocto, Automotive Grade Linux, Qt, Jenkins, Gitlab, Github Actions and more.
  • Incredibuild for Automotive rapidly accelerates automotive development on-prem and in the cloud, empowering dev teams to focus on quality, safety, and innovation while meeting key milestones.
  • In today's economic environment, releasing software faster and more efficiently is key, especially when it comes to 'Software on Wheels.'"
  • Auto manufacturers developing automotive software as well as independent software vendors can utilize Incredibuild for Automotive when helping build next-generation automotive technologies such as self-driving cars and smart cockpits.

Curavit Raises $5 Million in Series A Funding to Accelerate Growth in Digital Therapeutics Clinical Research

Retrieved on: 
Monday, November 14, 2022
Veteran, Growth, OVP, CRO, Technology, Veeva Systems, Curio, Lark Health, Therapy, News, NEW, Cloud computing, CAGR, Industry, COO, Time, Education, Research, Multimedia, Investment, Patient, Adoption, COVID-19, Single-frequency network, CEO, VP, DCT, Digital technology, Pharmaceutical industry, Medical imaging, DCTS

PHILADELPHIA and NEW YORK, Nov. 14, 2022 /PRNewswire/ --  Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs), today announced it raised $5 million in Series A funding to accelerate its growing portfolio of research in the global digital therapeutics (DTx) market (projected to grow at a CAGR of 31.4% through 2026). The new funding will be used to expand the company's DCT capabilities, partnerships, and market adoption of Curavit's virtual CRO services and platform for prescription and non-prescription digital therapeutics trials.

Key Points: 
  • The funding was led by early-stage technology investor Osage Venture Partners with additional investment from Royal Street Ventures and Narrow Gauge Ventures .
  • "This is an important milestone for Curavit and the industry's continued momentum in digital therapeutics and decentralized approaches to clinical research," said Joel Morse, co-founder and CEO of Curavit.
  • More than half of its customer base are emerging digital therapeutics companies whose clinical research needs align with Curavit's focus on virtual site services and DCT expertise.
  • Curavit Clinical Research is a full-service, virtual contract research organization (VCRO), focused on designing and executing digital-first decentralized clinical trials (DCTs).

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

Retrieved on: 
Friday, November 11, 2022
Clinical trial, FDi Magazine, US FDA, Gene, Plasma protein binding, Ownership, Cell, NDA, CRO, Marketing, MAH, Research, CTA, FIH, Drug development, NMPA, Cros, Pharmaceutical industry, Fine chemical, IND

Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.

Key Points: 
  • Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.
  • Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program.
  • Strategies for an East-West MRCT include:
    - Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.
  • Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases.

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

Retrieved on: 
Friday, November 11, 2022
Sutro Biopharma, FDi Magazine, US FDA, Gene, Plasma protein binding, Ownership, Cell, NDA, CRO, Marketing, MAH, Research, NMPA, Cros, Pharmaceutical industry, Fine chemical, IND

Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.

Key Points: 
  • Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.
  • Commenting on Novotechs experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program.
  • Strategies for an East-West MRCT include:
    Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.